Kuros Biosciences AG Sustainability Reports
Kuros Biosciences AG is a commercial-stage biopharmaceutical company focused on the development and commercialization of advanced spinal fusion biologics and bone graft substitutes. Its primary product line, MagnetOs, is designed to stimulate bone regeneration and improve patient recovery following surgical procedures.
Sector: Professional & technical services
Country: Switzerland
Exchange: SIX Swiss Exchange
ISIN: CH0325814116
10 reports from 2015 to 2024